Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter randomized, double-blind, controlled study of NGX-4010 [capsaicin; NeurogesX] for the treatment of painful HIV-associated neuropathy

Next Previous
Trial Profile

A multicenter randomized, double-blind, controlled study of NGX-4010 [capsaicin; NeurogesX] for the treatment of painful HIV-associated neuropathy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capsaicin (Primary) ; Lidocaine
  • Indications Neuropathic pain; Polyneuropathy
  • Focus Therapeutic Use
  • Sponsors NeurogesX

Most Recent Events

  • 18 Oct 2010 NeurogesX plans to submit a supplemental new drug application (sNDA) to the US FDA in the first half of 2011, utlilising data from this and another (70005965) study, according to a company media release.
  • 02 Sep 2010 Results of a planned pooled analysis of this trial and 3 other RCTs [700005976, 70005965 and 700027018] were presented at the 13th World Congress on Pain.
  • 06 Feb 2010 Results have been presented at the 17th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top